U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542860) titled 'Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients' on April 14.
Brief Summary: Elderly patients with cardiovascular disease face a high risk of both thrombotic and bleeding events when receiving antithrombotic therapy. The optimal dose of aspirin for secondary prevention in this population remains uncertain, particularly in Chinese elderly individuals. This multicenter, prospective cohort study aims to evaluate the effectiveness and safety of a lower dose of aspirin (50 mg daily) compared with the standard dose (100 mg daily) for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in Chinese pat...